Delcath Systems has recently announced a major achievement in the advancement of HEPZATO™, their groundbreaking melphalan/Hepatic Delivery System. As of April 1, 2024, HEPZATO has been granted a permanent J-Code (J9248), a specific and enduring Healthcare Common Procedure Coding System (HCPCS) code. This J-Code will greatly simplify the reimbursement process for HEPZATO, ensuring a smooth and efficient billing and payment system.
This significant milestone represents a pivotal moment for Delcath Systems in the commercialization of HEPZATO. The J-Code will not only benefit the company, but also healthcare providers and patients alike. By streamlining the billing and payment process, HEPZATO will become more accessible and readily available to those in need.
It is important to highlight that the HEPZATO KIT, which includes melphalan hydrochloride injection in powder form, lyophilized, is an integral component of the HEPZATO Hepatic Delivery System for intra-arterial use. For comprehensive and detailed instructions regarding usage and safety, it is essential to consult the complete prescribing information for HEPZATO.
Delcath Systems’ achievement in obtaining a permanent J-Code for HEPZATO marks a significant step forward in the field of medical innovation. With this coding system in place, the future looks promising for both the company and individuals seeking effective healthcare solutions.
Delcath Systems, Inc. (DCTH) Stock Price Declines Below 200-Day Moving Average: Potential Negative Momentum
On January 31, 2024, Delcath Systems, Inc. (DCTH) experienced a decline in its stock price. The stock was trading below its 200-day simple moving average, indicating a potential lack of positive price momentum.
The price of DCTH shares had decreased by $0.16 since the market last closed, representing a drop of 3.48%. The stock had closed at $4.44.
The fact that DCTH was trading below its 200-day simple moving average suggests that the stock may be facing some downward pressure.
Furthermore, the 3.48% drop in the stock price since the market last closed suggests that there may be some negative sentiment surrounding DCTH.
However, it is worth noting that the stock had risen by $0.31 in pre-market trading.
It is important to approach stock performance with caution and conduct thorough research before making any investment decisions. While the provided information gives a snapshot of DCTH’s stock performance on January 31, 2024, it is crucial to consider additional factors such as company news, industry trends, and market conditions to gain a comprehensive understanding of the stock’s potential future performance.
DCTH Stock Performance Plummets: Revenue, Net Income, and EPS Show Significant Declines on January 31, 2024
DCTH Stock Performances on January 31, 2024:
– DCTH experienced a significant decline in its stock performance.
– Total revenue decreased by 23.52% compared to the previous year.
– Total revenue in the third quarter decreased by 12.32% compared to the previous quarter.
– Net income decreased by 42.34% compared to the previous year.
– Net income in the third quarter decreased by 182.42% compared to the previous quarter.
– Earnings per share (EPS) decreased by 14.74% compared to the previous year.
– EPS in the third quarter decreased by 97.08% compared to the previous quarter.
– These declines indicate potential challenges and financial struggles for DCTH.
– Investors and stakeholders should closely monitor DCTH’s financial performance.
